Literature DB >> 15990567

Analysis of the effect of highly active antiretroviral therapy during acute HIV-1 infection on HIV-specific CD4 T cell functions.

Christine A Jansen1, Iris M De Cuyper, Radjin Steingrover, Suzanne Jurriaans, Sanjay U C Sankatsing, Jan M Prins, Joep M A Lange, Debbie van Baarle, Frank Miedema.   

Abstract

BACKGROUND: It has been reported that antiretroviral therapy (HAART) during acute HIV-1 infection may rescue HIV-1-specific CD4 T cell responses.
OBJECTIVE: To determine the duration of this preserved response by investigating the long-term effects of HAART during acute infection on HIV-specific CD4 T cell function related to possible immune control during subsequent therapy interruption.
METHODS: A longitudinal analysis followed HIV-specific CD4 T cell reactivity in 17 individuals with well-documented acute HIV-1 infection where five out of 11 HAART-treated patients stopped therapy and six were untreated. Peripheral blood mononuclear cells were stimulated with overlapping peptide pools derived from Gag and Nef. Production of interferon-gamma (IFN-gamma) and interleukin-2 (IL-2) by CD4 T cells was analysed together with proliferative responses.
RESULTS: Absolute numbers, but not percentages, of Gag-specific IFN-gamma-, IL-2- or IFN-gamma/IL-2-producing CD4 T cells were increased in treated compared with untreated individuals up to 2 years after seroconversion. HAART during acute HIV-1 infection was associated with lower viral load but did not result in increased proliferation of HIV-specific CD4 T cells. One out of five individuals who discontinued therapy showed evidence for immune control. However, patients who failed to control viraemia also had measurable proliferative HIV-specific CD4 T cell responses and preserved numbers of cytokine-producing CD4 T cells.
CONCLUSIONS: Early HAART during acute HIV-1 infection resulted in higher numbers of HIV-specific IFN-gamma- and IL-2-producing CD4 T cells, but this preservation in four out of five patients was not associated with control of viraemia upon treatment interruption.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15990567     DOI: 10.1097/01.aids.0000176214.17990.94

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  19 in total

1.  Highly active anti-retroviral therapy (HAART)-induced maintenance of adaptive but not innate immune parameters is associated with protection from HIV-induced mortality.

Authors:  J Stebbing; M Bower; S Mandalia; M Nelson; B Gazzard
Journal:  Clin Exp Immunol       Date:  2006-08       Impact factor: 4.330

2.  Low antigen-specific CD4 T-cell immune responses despite normal absolute CD4 counts after long-term antiretroviral therapy an African cohort.

Authors:  Rose Nabatanzi; Lois Bayigga; Isaac Ssinabulya; Agnes Kiragga; Andrew Kambugu; Joseph Olobo; Moses Joloba; Moses R Kamya; Harriet Mayanja-Kizza; Damalie Nakanjako
Journal:  Immunol Lett       Date:  2014-09-26       Impact factor: 3.685

Review 3.  Soluble mediators of inflammation in HIV and their implications for therapeutics and vaccine development.

Authors:  Sheila M Keating; Evan S Jacobs; Philip J Norris
Journal:  Cytokine Growth Factor Rev       Date:  2012-06-27       Impact factor: 7.638

4.  Changes in paracrine interleukin-2 requirement, CCR7 expression, frequency, and cytokine secretion of human immunodeficiency virus-specific CD4+ T cells are a consequence of antigen load.

Authors:  John C Tilton; Marlise R Luskin; Alison J Johnson; Maura Manion; Claire W Hallahan; Julia A Metcalf; Mary McLaughlin; Richard T Davey; Mark Connors
Journal:  J Virol       Date:  2006-12-20       Impact factor: 5.103

5.  Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.

Authors:  Adriana Weinberg; Ruth Dickover; Paula Britto; Chengcheng Hu; Julie Patterson-Bartlett; Joyce Kraimer; Howard Gutzman; William T Shearer; Mobeen Rathore; Ross McKinney
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

6.  Human immunodeficiency virus (HIV)-specific T helper responses fail to predict CD4+ T cell decline following short-course treatment at primary HIV-1 infection.

Authors:  J Fox; T J Scriba; N Robinson; J N Weber; R E Phillips; Sarah Fidler
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

Review 7.  Acute HIV infection: the impact of anti-retroviral treatment on cellular immune responses.

Authors:  C B Hicks; C Gay; G Ferrari
Journal:  Clin Exp Immunol       Date:  2007-06-21       Impact factor: 4.330

8.  Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines.

Authors:  Sunil Kannanganat; Bill G Kapogiannis; Chris Ibegbu; Lakshmi Chennareddi; Paul Goepfert; Harriet L Robinson; Jeffrey Lennox; Rama Rao Amara
Journal:  J Virol       Date:  2007-08-29       Impact factor: 5.103

Review 9.  The detection and management of early HIV infection: a clinical and public health emergency.

Authors:  M Kumi Smith; Sarah E Rutstein; Kimberly A Powers; Sarah Fidler; William C Miller; Joseph J Eron; Myron S Cohen
Journal:  J Acquir Immune Defic Syndr       Date:  2013-07       Impact factor: 3.731

10.  Distortion of memory Vδ2 γδ T cells contributes to immune dysfunction in chronic HIV infection.

Authors:  Zhen Li; Yanmei Jiao; Yu Hu; Lianxian Cui; Dexi Chen; Hao Wu; Jianmin Zhang; Wei He
Journal:  Cell Mol Immunol       Date:  2014-09-15       Impact factor: 11.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.